Subscribe to RSS
DOI: 10.1055/s-0042-1755380
A Pre-Post Interventional Study for Evaluating the Usefulness of Homoeopathic Medicine Nux vomica to Combat the Side Effects of Liposomal Amphotericin B Injection in the Cases of Mucormycosis
Funding We received no funding for the study.Abstract
Introduction India reported a recent surge in mucormycosis cases, after outbreak of coronavirus disease 2019. Treatment for this entity is multifaceted and involves surgical debridement of affected tissues and antifungal treatment. In current practice, amphotericin B and isavuconazole are the two antifungal agents recommended for the primary therapy of mucormycosis. Possible side effects of liposomal form of amphotericin B (LAmB) include fever, chills, loss of appetite, nausea, vomiting and headache after the infusion is started. Nux vomica is a homoeopathic medicine and is one of the best remedies with which to commence treatment of cases that have been drugged by mixtures, bitters, vegetable pills but only if symptoms correspond. The aim of this study was to observe the effectiveness of homoeopathic medicine Nux vomica to combat the side effects of LAmB injection in the cases of mucormycosis.
Methods Total 55 diagnosed cases of mucormycosis, admitted in the Tertiary Care Centre (Govt. of Delhi), were enrolled in the study as per inclusion criteria. After reportorial analysis, Nux vomica 30C was given to the patients from 2nd day of administration of LAmB. Gastrointestinal Symptom Rating Scale was used to assess the improvement in the cases by comparing the scores obtained before and after the treatment.
Result Out of 55 cases, 42 showed marked improvement from 7th day onwards after administration of Nux vomica 30C. Result was analysed by using one-way repeated-measures analysis of variance and post hoc Tukey Honest Significant Difference and was found statistically significant at 5% level of significance.
Conclusion This study indicates that Nux vomica is possibly a useful medicine to combat the side effects of LAmB injection in the cases of mucormycosis. Nux vomica helped to improve the condition of the patients and enabled them to continue the required conventional treatment for their speedy recovery. More studies are required for further validation.
Ethical Consideration
In this study, no new drug was experimented on nor was any new treatment protocol adopted. Intervention was strict accordance with homoeopathic principles. Prior to enrolment, each patient was provided with a patient information sheet in local vernacular language, detailing the objectives, risks and benefits of participating, also about maintaining confidentiality of their identity. Written informed consent was also obtained. However, the patient was free to withdraw from the study at any time. Approval was obtained from the concerned authority of the Tertiary Care Centre. The study conformed to the declaration of Helsinki for ethical conduct on human experimentation.
Authors' Contribution
M.C. and P.R. contributed to the concept, data interpretation, statistical analysis and preparation of the article. N.G. contributed in conduction of the study and N.S. contributed to data acquisition and literature search for the article.
Publication History
Article published online:
07 September 2022
© 2022. Thieme. All rights reserved.
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Mucormycosis WHO. 2021 . Accessed July 19, 2022 from: https://www.who.int/india/emergencies/coronavirus-disease-(covid-19)/mucormycosis
- 2 Kumar A, Gupta V. Rhino-orbital Cerebral Mucormycosis. PMC US NLM, NIH [Online]. 2021 . Accessed July 19, 2022 from: https://www.ncbi.nlm.nih.gov/books/NBK557429/
- 3 Information for Healthcare Professionals about Mucormycosis. CDC, USA. 2020 . Accessed July 19, 2022 from: https://www.cdc.gov/fungal/diseases/mucormycosis/health-professionals.html
- 4 Palejwala SK, Zangeneh TT, Goldstein SA, Lemole GM. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. Surg Neurol Int 25-May-2016;7:61. Accessed July 19, 2022 from: https://surgicalneurologyint.com/surgicalint-articles/an-aggressive-multidisciplinary-approach-reduces-mortality-in-rhinocerebral-mucormycosis/
- 5 Avnish S. Mucormycosis (Zygomycosis) Treatment & Management. Medscape [Online]. 2021 . Accessed July 19, 2022 from: https://emedicine.medscape.com/article/222551-treatment#d9
- 6 Amphotericin B Liposome Suspension For Reconstitution - Uses, Side Effects, and More. Webmd [Online]. 2012 . Accessed July 19, 2022 from: https://www.webmd.com/drugs/2/drug-4780/amphotericin-b-liposome-intravenous/details
- 7 Bhati R, Singh A, Saharan VA, Ram V, Bhandari A. Strychnos nux-vomica seeds: Pharmacognostical standardization, extraction, and antidiabetic activity. J Ayurveda Integr Med 2012; 3 (02) 80-84
- 8 Boericke W. Boericke's New Manual of Homoeopathic Materia Medica with Repertory. Third revised and Augmented edition, 35th impression. Delhi: B.Jain Publishers Pvt. Ltd; 2014: 422-424
- 9 Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?. Lancet Respir Med 2021; 9 (08) e77 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00265-4/fulltext Accessed July 19, 2022
- 10 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15 (04) 102146 DOI: 10.1016/j.dsx.2021.05.019.
- 11 Ministry of Health and Family welfare. COVID-19 GoM reiterates importance of COVID Appropriate Behaviour as States unlock in a calibrated manner second wave still not over; Concerns in Pockets highlighted. PIB Delhi: 2021 . Accessed July 19, 2022 from: https://pib.gov.in/PressReleasePage.aspx?PRID=1730873
- 12 Chander J, Kaur M, Singla N. et al. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi (Basel) 2018; 4 (02) 46
- 13 Roden MM, Zaoutis TE, Buchanan WL. . Knudsen, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 2005 41. 634-653 . Accessed July 19, 2022 from: https://academic.oup.com/cid/article/41/5/634/327691?login=false.
- 14 Delhi Government Health Services. Guideline for management of Mucormycosis in Covid – 19 Patients.. 17 May, 2021. Accessed July 19, 2022 from: https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf
- 15 Micromedex IBM, Amphotericin B. Mayo Clinic. 2021. Accessed July 19, 2022 from: https://www.mayoclinic.org/drugs-supplements/amphotericin-b-intravenous-route-injection-route/side-effects/drg-20061771
- 16 Nash EB. Leaders in Homoeopathic Therapeutics with Grouping and Classification, Sixth Edition, 38th impression. New Delhi: B. Jain Publishers Pvt. Ltd.; 2014: 1-9
- 17 Allen HC. . Nux Vomica. Allen's Keynotes Rearranged and Classified with Leading Remedies of the Material Medica and Bowel Nosodes, 10th edition, 33rd impression. New Delhi: B. Jain Publishers Pvt. Ltd.; 2017: 223-225
- 18 Kent JT. . Nux Vomica. Lectures on Homoeopathic Materia Medica. 15th Impression. New Delhi: B. Jain Publishers Pvt. Ltd.; 2017: 803-809